View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 21, 2021

Landos and Icahn School of Medicine partner for Crohn’s disease drug trial

The Phase II trial will assess the efficacy, safety and mechanisms of omilancor in nearly 40 moderate-to-severe CD patients. 

Landos Biopharma has signed a research partnership with the Icahn School of Medicine at Mount Sinai to carry out a Phase III clinical trial of its investigational drug, omilancor, in moderate-to-severe Crohn’s disease (CD) patients.

Developed using Landos’ LANCE Advanced A.I. platform, omilancor is a new, oral, gut-restricted, small-molecule drug.

Omilancor acts on the Lanthionine Synthetase C-Like 2 (LANCL2) pathway affecting the gastrointestinal tract, Landos noted.

The randomised, double-blind Phase II trial will assess the efficacy, safety and mechanisms of omilancor in moderate-to-severe CD patients.

It will enrol nearly 40 subjects, who will be categorised to receive either an 880mg dose of omilancor or the standard of care, adalimumab (Humira), once a day for 12 weeks.

During the induction period, patients will be monitored at baseline, two, six and 12 weeks for evaluating symptoms, disease-linked biomarkers and patient-reported outcomes.

Intestinal biopsy specimens, stool and peripheral blood will be broadly assessed at the Laboratory of Mucosal Immunology at Mount Sinai Hospital.

Furthermore, the US National Institutes of Health (NIH) unit National Institute of Diabetes and Digestive and Kidney Diseases granted $3m to Landos to fund the Phase II trial of omilancor.

Landos Biopharma chairman, president and CEO Dr Josep Bassaganya-Riera said: “Entering this partnership with the Icahn School of Medicine at Mount Sinai highlights our ability to pursue innovative clinical and translational studies that build on our pioneering immunometabolism franchise in autoimmune diseases.

“We are excited to expand the investigation of our Phase III ready product candidate, omilancor, in this mechanistic Phase II study in CD to further validate how activation of the LANCL2 pathway by omilancor enhances regulatory T cell (Treg) function in the gastrointestinal tract.”

A chronic, autoimmune disease of the gastrointestinal (GI) tract, CD causes inflammation, irritation and ulcers in any segment of the GI tract.

In 2018, Landos dosed the first cohort of subjects in a Phase l study designed to investigate the safety and tolerability of BT-11 for the treatment of inflammatory bowel disease, including ulcerative colitis and CD.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU